Opicapone Contraindications: Essential Restrictions for At-Risk Groups

　　As a COMT inhibitor,Opicapone plays a defined role in regulating dopamine metabolism.However,its impact on the catecholamine system necessitates strict contraindications in specific populations to prevent adverse events:

　　1.Contraindicated with Non-Selective MAO Inhibitors(MAOIs)

　　Combining Opicapone with MAOIs can lead to excessive catecholamine elevation,potentially triggering life-threatening cardiovascular crises such as hypertensive emergencies.This combination is strictly prohibited.

　　2.Forbidden in Pheochromocytoma Patients

　　Pheochromocytomas secrete large amounts of catecholamines.Opicapone’s metabolic inhibition further exacerbates norepinephrine and epinephrine accumulation,significantly worsening disease risks.

　　3.Contraindicated in Paraganglioma and Similar Tumors

　　Like pheochromocytoma,paraganglioma patients are at risk of catecholamine imbalance and circulatory overload from Opicapone use,making it contraindicated.

　　4.Caution for Catecholamine Metabolism Disorders

　　Patients with suspected catecholamine metabolism abnormalities require careful evaluation before Opicapone therapy,as its mechanism may disrupt physiological balances.

　　5.Caution for Severe Psychiatric or Impulse Control Disorders

　　While not absolute contraindications,Opicapone’s dopamine modulation may affect behavioral control in these populations,warranting risk assessment and monitored use.

　　6.Hypersensitivity Contraindication

　　Individuals allergic to Opicapone or its excipients must avoid the drug to prevent allergic reactions.

　　Key Risk Insight:

　　Opicapone’s contraindications primarily center on“catecholamine overactivity”disorders and specific drug interactions.Its metabolic enhancement effects can become liabilities in these contexts,demanding stringent adherence to restrictions.